BAFF, A newcomer to the lupus party
based on the insertion of CD40 ligand (CD40L) on the former cells, into CD40 on the latter. Actually, BAFF can be substituted for CD40L in this process. 7 This can favour proliferation of the cells, as suggested by target organ infiltration in BAFF knocked-in (KI) mice with the help of T-cells through TNF. However, mating these mice with TNF knocked-out partner does not protect their offspring from autoimmune infiltration indicating that B-cells have the capacity to proliferate on their own. 8 Further insights 9 into BAFF have been gained using the hen-egg lysozyme (HEL) model where anti-HEL antibodies (Ab) overcome the anergy on a BAFF-KI background. 9 This results from the interplay between the maturation stage, the affinity of the B-cell receptor for HEL and the number of B-lymphocytes competing for BAFF. Obviously, only those autoreactive B-cells that mature sufficiently to acquire responsiveness to survival signals are rescued from apoptosis by BAFF. In this respect, a critical checkpoint, around the T1-T2 sequence of B-cell ontogenesis, 10 have been recognized. Owing to the fact that MZ B-cells are most exposed to polyclonal activation, the need to prevent autoreactive BT1-BT2 cells from colonizing this site is paramount.
The seminal finding of an autoimmune phenotype in BAFF-KI mice 2 has prompted the experts in the field to determine its role in human SLE. A proportion of patients do indeed exhibit elevated levels of soluble BAFF 11 . The trouble is that the remainder display circulating BAFF levels within or perplexingly, below the normal range. In addition, the parallel with autoAb titres is variable and the correlation with disease activity extremely modest. 12 One explanation is that BAFF is not accessible, being inserted into B-cell receptors for BAFF, confined in anti-BAFF Ab-containing immune complexes or excreted in the urines of patients with glomerulonephritis. 13 Another explanation is that BAFF is not recognized in the assay, due to the presence of heterotrimers of BAFF and APRIL 14 or to the production of aberrant forms of the molecule, such as delta-BAFF or psi-BAFF. 15 As BAFF likely contributes to the pathogenesis of SLE, the rationale is building for an approach targeting this system. A human monoclonal Ab has first been generated 16 . Disappointingly, the protein products of cells transfected with the BR3, TACI or BCMA gene, Given the crucial role for B-cells in systemic lupus erythematosus (SLE), 1 it stands to reason that cytokines of the tumour necrosis factor (TNF) group are under suspicion. Prominent among these are the B-cellactivating factor belonging to the TNF family (BAFF), also designated B-Lymphocyte Stimulator and a proliferation-inducing ligand (APRIL). Current animal studies unveil an unexpected link between autoimmunity (particularly SLE 2 ) and cancer (particularly chronic lymphocytic leukaemia 3 ). The introduction of BAFF antagonists into therapeutic trials is also testimony to the impact of this cytokine on such disorders 4 .
In fact, BAFF has proved to be heterogeneous. 5 This presents as a membrane-bound or a cell-free molecule, shapes a monomer or a virus-like cluster that gathers together up to 60 specimens of BAFF, and gets organized as a homotrimer made up of three BAFF monomers or a heteropolymer combining BAFF and APRIL in different ways. BAFF is expressed on the cell surface and cleaved thereafter, whereas APRIL is cleaved inside the cell and subsequently released. Two receptors bind both molecules: these are the transmembrane activator and calcium modulator and cyclophilin ligand interactor (referred to as TACI), and to the B-cell maturation antigen (referred to as BCMA). Another two receptors are specific: BR3 and a proteoglycan which are dedicated to BAFF and APRIL, respectively. Their role remains elusive. A number of cells have been claimed to produce BAFF. These include all sorts of monocytes, astrocytes and synoviocytes, stromal cells in the bone-marrow and neutrophils, activated T-cells and even autoreactive B-lymphocytes buried into the salivary glands of patients with primary or secondary Sjögren's syndrome. 6 The effects assigned to BAFF are numerous. This cytokine has indeed emerged as a potent survival factor for immature B-lymphocytes, as established by in vitro experiments, with the largest increase seen for transitional type 2 (T2) and marginal zone (MZ) B-cells. Some experts think that T-lymphocytes are not indispensable to the class switch of B-lymphocytes, are not recognized by BAFF in the presence of the Ab. However, some successes deserve a mention. It has been shown that i.v immunoglobulin (Ig) preparations contain IgG that bind to, and prevent BAFF from exerting its anti-apoptotic effects. 17 Decoy receptors have also been used in the mouse, either BR3-Ig that retains BAFF but not APRIL or TACI-Ig that grasps BAFF as well as APRIL. 18 Interestingly, BAFF fused to a toxin has met success in treated and untreated patients with chronic lymphocytic leukaemia. 19 Toxin-conjugated BAFF enters and kills the cells, while toxin alone does not. Finally, anti-BR3 are being designed, that mimic the insertion of BAFF into BR3, through an epitope encompassing the binding site of BR3 for BAFF. 20 In conclusion, the complexity of the BAFF system seems ever-growing. Its central role to the survival of autoreactive B-lymphocytes points to an attractive target for treatment of SLE, but there is still a long way to go before getting into clinical practice, on a routine basis.
